![AACR 2022: YH008, a PD-1-CD40 Bispecific Antibody, Inhibits Tumor Growth In Vivo Through PD-1-Dependent Activation of CD40 Signaling - Biocytogen AACR 2022: YH008, a PD-1-CD40 Bispecific Antibody, Inhibits Tumor Growth In Vivo Through PD-1-Dependent Activation of CD40 Signaling - Biocytogen](https://i0.wp.com/biocytogen.com/wp-content/uploads/2022/04/11111-1.png?fit=1507%2C879&ssl=1)
AACR 2022: YH008, a PD-1-CD40 Bispecific Antibody, Inhibits Tumor Growth In Vivo Through PD-1-Dependent Activation of CD40 Signaling - Biocytogen
![Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting - PR Newswire APAC Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting - PR Newswire APAC](https://mma.prnasia.com/media2/1794036/image_5002937_41620453.jpg?p=medium600)
Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting - PR Newswire APAC
![Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting](https://mma.prnasia.com/media2/1794038/image_5002937_41620788.jpg?p=medium600)
Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
![AACR 2022: Humanized PVRIG Mice: A Novel Tool for Evaluating Anti-PVRIG Immunotherapies - Biocytogen AACR 2022: Humanized PVRIG Mice: A Novel Tool for Evaluating Anti-PVRIG Immunotherapies - Biocytogen](https://i0.wp.com/biocytogen.com/wp-content/uploads/2022/04/101111.png?fit=1235%2C822&ssl=1)
AACR 2022: Humanized PVRIG Mice: A Novel Tool for Evaluating Anti-PVRIG Immunotherapies - Biocytogen
![Immunicom Presents New Data at AACR 2022 of LW-02 Cartridge Immunopheresis® Therapy from Ongoing mTNBC Clinical Trial in Chemo-Refractory Patients - Immunicom Immunicom Presents New Data at AACR 2022 of LW-02 Cartridge Immunopheresis® Therapy from Ongoing mTNBC Clinical Trial in Chemo-Refractory Patients - Immunicom](https://immunicom.com/wp-content/uploads/2022/04/Dr-Wysocki-with-Poster-1.jpg)